Richard W Joseph

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team

Aleksandar Sekulic, Jeffrey M Trent, Sally Hunsberger, 2015, Molecular Cancer Therapeutics.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Merrick I Ross, Susan M Swetter, Brian Gastman, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.

ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma

Jeanette E Eckel-Passow, Brian M Bot, J. Cheville, 2014, BMC Urology.